COMPARATIVE ANALYSIS OF REGULATORY PATHWAY OF CLASS C (INFUSION PUMP) AND CLASS D (PACEMAKER) MEDICAL DEVICES IN INDIA WITH CLASS II (INFUSION PUMP) AND CLASS III (PACEMAKER) MEDICAL DEVICES IN THE USA

Abstract

Objectives: To compare the approval process of selected medical devices—Class C (infusion pump), and Class D (pacemaker) in India and in the United States.

Methods: A comparative review of regulatory frameworks was conducted using the Medical Devices Rules, 2017 under the Central Drugs Standard Control Organization (CDSCO) and the device classification system of the U.S. Food and Drug Administration (FDA). Data were analyzed based on risk classification, licensing procedures, conformity assessment, and premarket requirements.

Results: Medical Devices in India are categorised into Classes A (low risk) to D (high risk). Class C devices (infusion pumps) and Class D devices (pacemakers) undergo stringent evaluation, including clinical evidence and approval by the Central Licensing Authority. Approval process in India requires online CDSCO submission, technical dossiers, ISO 13485 compliance, fees ranging from ₹5,000 to ₹50,000 per application, and review timeframes of 6 to 9 months. In the United States, the FDA classifies them into Class I–III; Class II devices like infusion pumps generally follow the 510(k)-pathway, demonstrating substantial equivalence, whereas Class III devices, such as pacemakers, require Premarket Approval (PMA) supported by extensive clinical data. In the USA, Class II and III devices must go through the PMA or 510(k) processes, which can cost up to US$ 540,783, entail extensive safety, performance, and clinical data investigations, and take 3 to 12 months to approve.

Conclusion: Both countries adopt risk-based frameworks with increasing regulatory rigor for higher-risk devices. However, the U.S. emphasizes the requirements of Pre- Market Approval, while India relies on CDSCO licensing and conformity assessments.